Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy

Experimental Neurology

Volumn 287, Issue , 2017, Pages 54-64

  Simeone, Timothy A ^a   Matthews, Stephanie A ^a   Samson, Kaeli K ^a   Simeone, Kristina A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epilepsy; Kcna1; Ketogenic diet; Kv1.1; Nutrition; Peroxisome proliferator activated receptor; PPARgamma2; Seizure

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; POTASSIUM CHANNEL KV1.1; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; 3 HYDROXYBUTYRIC ACID; ANILIDE; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; CONVULSANT AGENT; FLUROTHYL; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CELL NUCLEUS; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC VARIABILITY; KETOGENIC DIET; KNOCKOUT MOUSE; LATENT PERIOD; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SEIZURE; THERAPY EFFECT; TONIC CLONIC SEIZURE; WILD TYPE MOUSE; AGE; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DIET THERAPY; DISEASE MODEL; DRINKING; DRUG EFFECTS; EPILEPSY; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; NEWBORN; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

3-HYDROXYBUTYRIC ACID; AGE FACTORS; ANILIDES; ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; BLOOD GLUCOSE; BRAIN; CONVULSANTS; DISEASE MODELS, ANIMAL; DRINKING; EPILEPSY; FLUROTHYL; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HYPOGLYCEMIC AGENTS; KETOGENIC DIET; KV1.1 POTASSIUM CHANNEL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84995394885     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.08.006     Document Type: Article

References (80)

1. Abdallah, D.M., Anticonvulsant potential of the peroxisome proliferator-activated receptor γ agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res. 1351 (2010), 246–253.
2. Adabi Mohazab, R., Javadi-Paydar, M., Delfan, B., Dehpour, A.R., Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice. Epilepsy Res. 101 (2012), 28–35.
3. Araki, H., Kobayashi, Y., Hashimoto, Y., Futagami, K., Kawasaki, H., Gomita, Y., Characteristics of flurothyl-induced seizures and the effect of antiepileptic drugs on flurothyl-induced seizures in Mongolian gerbils. Pharmacol. Biochem. Behav. 74:1 (2002), 141–147.
4. Barker-Haliski, M.L., Dahle, E.J., Heck, T.D., Pruess, T.H., Vanegas, F., Wilcox, K.S., White, H.S., Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model. J. Pharmacol. Exp. Ther. 353:2 (2015), 318–329, 10.1124/jpet.114.222513.
5. Bernardo, A., Minghetti, L., PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006), 93–109.
6. Boes, K., Russmann, V., Ongerth, T., Licko, T., Salvamoser, J.D., Siegl, C., Potschka, H., Expression regulation and targeting of the peroxisome proliferator-activated receptor γ following electrically-induced status epilepticus. Neurosci. Lett. 604 (2015), 151–156.
7. Bough, K.J., Wetherington, J., Hassel, B., Pare, J.F., Gawryluk, J.W., Greene, J.G., Shaw, R., Smith, Y., Geiger, J.D., Dingledine, R.J., Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 60 (2006), 223–235.
8. Bugge, A., Grontved, L., Aagaard, M.M., Borup, R., Mandrup, S., The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment. Mol. Endocrinol. 23 (2009), 794–808.
9. Castillo, G., Brun, R.P., Rosenfield, J.K., Hauser, S., Park, C.W., Troy, A.E., Wright, M.E., Spiegelman, B.M., An adipogenic cofactor bound by the differentiation domain of PPARgamma. EMBO J. 18 (1999), 3676–3687.
10. Chang, P., Terbach, N., Plant, N., Chen, P.E., Walker, M.C., Williams, R.S., Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69 (2013), 105–114.
11. Chuang, Y.C., Lin, T.K., Huang, H.Y., Chang, W.N., Liou, C.W., Chen, S.D., Chang, A.Y.W., Chan, S.H.H., Peroxisome proliferator-activated receptors gamma/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. J. Neuroinflammation, 9, 2012, 184.
12. Cullingford, T.E., The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot. Essent. Fat. Acids 70 (2004), 253–264.
13. Diab, A., Deng, C., Smith, J.D., Hussain, R.Z., Phanavanh, B., Lovett-Racke, A.E., Drew, P.D., Racke, M.K., Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002), 2508–2515.
14. Engel, T., Sanz-Rodgriguez, A., Jimenez-Mateos, E.M., Concannon, C.G., Jimenez-Pacheco, A., Moran, C., Mesuret, G., Petit, E., Delanty, N., Farrell, M.A., O'Brien, D.F., Prehn, J.H., Lucas, J.J., Henshall, D.C., CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. Brain 136 (2013), 577–592.
15. Fenoglio-Simeone, K., Mazarati, A., Sefidvash-Hockley, S., Shin, D., Wilke, J., Milligan, H., Sankar, R., Rho, J.M., Maganti, R., Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav. 16 (2009), 52–57.
16. Fenoglio-Simeone, K.A., Wilke, J.C., Milligan, H.L., Allen, C.N., Rho, J.M., Maganti, R.K., Ketogenic diet treatment abolishes seizure periodicity and improves diurnal rhythmicity in epileptic Kcna1-null mice. Epilepsia 50 (2009), 2027–2034.
17. Fong, W.H., Tsai, H.D., Chen, Y.C., Wu, J.S., Lin, T.N., Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol. Neurobiol. 41 (2010), 180–186.
18. Fraser, D.D., Whiting, S., Andrew, R.D., Macdonald, E.A., Musa-Veloso, K., Cunnane, S.C., Elevated polyunsaturated fatty acids in blood serum obtained from children on the ketogenic diet. Neurology 60 (2003), 1026–1029.
19. Freeman, J., Veggiotti, P., Lanzi, G., Tagliabue, A., Perucca, E., The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 68 (2006), 145–180.
20. Gahring, L.C., Persiyanov, K., Days, E.L., Rogers, S.W., Age-related loss of neuronal nicotinic receptor expression in the aging mouse hippocampus corresponds with cyclooxygenase-2 and PPAR gamma expression and is altered by long-term NS398 administration. J. Neurobiol. 62 (2005), 453–468.
21. Gano, L.B., Patel, M., Rho, J.M., Ketogenic diets, mitochondria, and neurological diseases. J. Lipid Res. 55 (2014), 2211–2228.
22. Grommes, C., Karlo, J.C., Caprariello, A., Blankenship, D., Dechant, A., Landreth, G.E., The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother. Pharmacol. 71:4 (2013), 929–936, 10.1007/s00280-013-2084-2.
23. Haces, M.L., Hernández-Fonseca, K., Medina-Campos, O.N., Montiel, T., Pedraza-Chaverri, J., Massieu, L., Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp. Neurol. 211:1 (2008), 85–96, 10.1016/j.expneurol.2007.12.029.
24. Han, Y., Xie, N., Cao, L., Zhao, X., Liu, X., Jiang, H., Chi, Z., Adenosine monophosphate-activated protein kinase and peroxisome proliferator-activated receptor gamma coactivator 1α signaling provides neuroprotection in status epilepticus in rats. Neurosci. Lett. 500 (2011), 133–138.
25. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J.M., Evans, R.M., Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15712–15717.
26. Heneka, M.T., Landreth, G.E., PPARs in the brain. Biochim. Biophys. Acta 1771 (2007), 1031–1045.
27. Hong, S., Huang, Y., Yu, X., Li, Y., Yang, J., Li, R., Deng, Y., Zhao, G., Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. Int. J. Dev. Neurosci. 26 (2008), 505–515.
28. Hong, S., Xin, Y., HaiQin, W., GuiLian, Z., Ru, Z., ShuQin, Z., HuQing, W., Li, Y., Yun, D., The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus. Neurol. Sci. 33 (2012), 559–566.
29. Hong, S., Xin, Y., HaiQin, W., GuiLian, Z., Ru, Z., ShuQin, Z., HuQing, W., Li, Y., Ning, B., YongNan, L., The PPARγ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus. Neurochem. Int. 63 (2013), 405–412.
30. Hughes, S.D., Kanabus, M., Anderson, G., Hargreaves, I.P., Rutherford, T., O'Donnell, M., Cross, J.H., Rahman, S., Eaton, S., Heales, S.J., The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J. Neurochem. 129 (2014), 426–433.
31. Ikeda, H., Taketomi, S., Sugiyama, Y., Shimura, Y., Sohda, T., Meguro, K., Fujita, T., Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40:2 Pt 1 (1990), 156–162.
32. Itoh, T., Fairall, L., Amin, K., Inaba, Y., Szanto, A., Balint, B.L., Nagy, L., Yamamoto, K., Schwabe, J.W., Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15 (2008), 924–931.
33. Iwanami, J., Mogi, M., Tsukuda, K., Min, L.J., Sakata, A., Jing, F., Iwai, M., Horiuchi, M., Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J. Hypertens. 28:8 (2010), 1730–1737.
34. Jeong, E.A., Jeon, B.T., Shin, H.J., Kim, N., Lee, D.H., Kim, H.J., Kang, S.S., Cho, G.J., Choi, W.S., Roh, G.S., Ketogenic diet-induced peroxisome proliferator-activated receptor-gamma activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp. Neurol. 232 (2011), 195–202.
35. Kawamura, M. Jr., Ruskin, D.N., Masino, S.A., Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels. J. Neurosci. 30:11 (2011), 3886–3895, 10.1523/JNEUROSCI.0055-10.2010.
36. Kawamura, M. Jr., Ruskin, D.N., Geiger, J.D., Boison, D., Masino, S.A., Ketogenic diet sensitizes glucose control of hippocampal excitability. J. Lipid Res. 55:11 (2014), 2254–2260, 10.1194/jlr.M046755.
37. Kim, d.Y., Davis, L.M., Sullivan, P.G., Maalouf, M., Simeone, T.A., van Brederode, J., Rho, J.M., Ketone bodies are protective against oxidative stress in neocortical neurons. J. Neurochem. 101:5 (2007), 1316–1326.
38. Kim, D.Y., Simeone, K.A., Simeone, T.A., Pandya, J.D., Wilke, J.C., Ahn, Y., Geddes, J.W., Sullivan, P.G., Rho, J.M., Ketone bodies mediate anti-seizure effects through mitochondrial permeability transition. Ann. Neurol. 78 (2015), 77–87.
39. Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J., Taniguchi, T., Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999), 582–586.
40. Kobow, K., Auvin, S., Jensen, F., Löscher, W., Mody, I., Potschka, H., Prince, D., Sierra, A., Simonato, M., Pitkänen, A., Nehlig, A., Rho, J.M., Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia 53 (2012), 1868–1876.
41. Kroker, A.J., Bruning, J.B., Review of the structural and dynamic mechanisms of PPARγ partial agonism. PPAR Res., 2015, 10.1155/2015/816856.
42. Larsen, P.J., Jensen, P.B., Sørensen, R.V., Larsen, L.K., Vrang, N., Wulff, E.M., Wassermann, K., Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52:9 (2003), 2249–2259.
43. Lu, M., Sarruf, D.A., Talukdar, S., Sharma, S., Li, P., Bandyopadhyay, G., Nalbandian, S., Fan, W., Gayen, J.R., Mahata, S.K., Webster, N.J., Schwartz, M.W., Olefsky, J.M., Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat. Med. 17 (2011), 618–622.
44. Lu, J., Wu, D.M., Zheng, Y.L., Hu, B., Cheng, W., Zhang, Z.F., Li, M.Q., Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein beta-mediated inflammatory response and oxidative stress. J. Immunol. 190 (2013), 3466–3479.
45. Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., Morales-Garcia, J.A., Martinez, A., Santos, A., Perez-Castillo, A., NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J. Neurosci. 27 (2007), 5766–5776.
46. Maalouf, M., Sullivan, P.G., Davis, L., Kim, D.Y., Rho, J.M., Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145:1 (2007), 256–264.
47. Maguire, J., Salpekar, J.A., Stress, seizures, and hypothalamic-pituitary-adrenal axis targets for the treatment of epilepsy. Epilepsy Behav. 26 (2013), 352–362.
48. Malapaka, R.R., Khoo, S., Zhang, J., Choi, J.H., Zhou, X.E., Xu, Y., Gong, Y., Li, J., Yong, E.L., Chalmers, M.J., Chang, L., Resau, J.H., Griffin, P.R., Chen, Y.E., Xu, H.E., Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J. Biol. Chem. 287 (2012), 183–195.
49. Mandrekar-Colucci, S., Sauerbeck, A., Popovich, P.G., McTigue, D.M., PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro, 5, 2013, e00129.
50. Masino, S.A., Rho, J.M., Mechanisms of ketogenic diet action. Noebels, J.L., Avoli, M., Rogawski, M.A., Olsene, R.W., Delgado-Escueta, A.V., (eds.) Jasper's Basic Mechanisms of the Epilepsies, 4th edition, 2012, National Center for Biotechnology Information, (US), Bethesda, MD.
51. Maurois, P., Rocchi, S., Pages, N., Bac, P., Stables, J.P., Gressens, P., Vamecq, J., The PPARgamma agonist FMOC-L-leucine protects both mature and immature brain. Biochem. Pharmacol. 62 (2008), 259–263.
52. Medina-Gomez, G., Virtue, S., Lelliott, C., Boiani, R., Campbell, M., Christodoulides, C., Perrin, C., Jimenez-Linan, M., Blount, M., Dixon, J., Zahn, D., Thresher, R.R., Aparicio, S., Carlton, M., Colledge, W.H., Kettunen, M.I., Seppänen-Laakso, T., Sethi, J.K., O'Rahilly, S., Brindle, K., Cinti, S., Oresic, M., Burceli, R., Vidal-Puig, A., The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 54:6 (2005), 1706–1716.
53. Medina-Gomez, G., Gray, S., Vidal-Puig, A., Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr. 10 (2007), 1132–1137.
54. Medina-Gomez, G., Gray, S.L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R.K., Jimenez-Linan, M., Blount, M., Yeo, G.S., Lopez, M., Seppänen-Laakso, T., Ashcroft, F.M., Oresic, M., Vidal-Puig, A., PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet., 3, 2007, e64.
55. Miglio, G., Rosa, A.C., Rattazzi, L., Collino, M., Lombardi, G., Fantozzi, R., PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem. Int. 55 (2009), 496–504.
56. Min, L.J., Mogi, M., Shudou, M., Jing, F., Tsukuda, K., Ohshima, K., Iwanami, J., Horiuchi, M., Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension, 2012, 10.1161/HYPERTENSIONAHA.112.192401.
57. Moreno, S., Farioli-Vecchioli, S., Cerù, M.P., Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004), 131–145.
58. Okada, K., Yamashita, U., Tsuji, S., Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 1102 (2006), 175–178.
59. Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O'Malley, B., Spiegelman, B., Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286 (1999), 1368–1371.
60. Roundtree, H.M., Simeone, T.A., Johnson, C., Matthews, S.A., Samson, K.K., Simeone, K.A., Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice. Sleep 39:2 (2016), 57–68, 10.5665/sleep.5444.
61. Sarruf, D.A., Yu, F., Nguyen, H.T., Williams, D.L., Printz, R.L., Niswender, K.D., Schwartz, M.W., Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150 (2009), 707–712.
62. Sauer, S., Ligands for the nuclear peroxisome proliferator-activated receptor gamma. Trends Pharmacol. Sci. 36 (2015), 688–704.
63. Shao, D., Rangwala, S.M., Bailey, S.T., Krakow, S.L., Reginato, M.J., Lazar, M.A., Interdomain communication regulating ligand binding by PPARgamma. Nature 396 (1998), 377–380.
64. Simeone, T.A., Simeone, K.A., Samson, K.K., Kim, d.Y., Rho, J.M., Loss of the Kv1.1 potassium channel promotes pathologic sharp waves and high frequency oscillations in in vitro hippocampal slices. Neurobiol. Dis. 54 (2013), 68–81.
65. Simeone, K.A., Matthews, S.A., Samson, K.K., Simeone, T.A., Targeting deficiencies in mitochondrial respiratory complex I and functional uncoupling exerts anti-seizure effects in a genetic model of temporal lobe epilepsy and in a model of acute temporal lobe seizures. Exp. Neurol. 251 (2014), 84–90.
66. Simeone, T.A., Samson, K.K., Matthews, S.A., Simeone, K.A., In vivo ketogenic diet treatment attenuates pathologic sharp waves and high frequency oscillations in in vitro hippocampal slices from epileptic Kv1.1α knockout mice. Epilepsia 55 (2014), e44–e49.
67. Simeone, K.A., Matthews, S.A., Rho, J.M., Simeone, T.A., Ketogenic diet treatment increases longevity in Kcna1-null mice, a model of sudden unexpected death in epilepsy. Epilepsia, 2016, 10.1111/epi.13444.
68. Stafstrom, C.E., Rho, J.M., The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol., 3, 2012, e59.
69. Steger, D.J., Grant, G.R., Schupp, M., Tomaru, T., Lefterova, M.I., Schug, J., Manduchi, E., Stoeckert, C.J. Jr., Lazar, M.A., Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 24 (2010), 1035–1044.
70. Sullivan, P.G., Rippy, N.A., Dorenbos, K., Concepcion, R.C., Agarwal, A.K., Rho, J.M., The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55 (2004), 576–580.
71. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., Spiegelman, B.M., mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994), 1224–1234.
72. Victor, N.A., Wanderi, E.W., Gamboa, J., Zhao, X., Aronowski, J., Deininger, K., Lust, W.D., Landreth, G.E., Sundararajan, S., Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006), 1653–1663.
73. Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B.B., Hamann, A., Hu, E., Spiegelman, B., Flier, J.S., Moller, D.E., Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97 (1996), 2553–2561.
74. Vidal-Puig, A.J., Considine, R.V., Jimenez-Liñan, M., Werman, A., Pories, W.J., Caro, J.F., Flier, J.S., Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99 (1997), 2416–2422.
75. Wang, H., Jiang, R., He, Q., Zhang, Y., Zhang, Y., Li, Y., Zhuang, R., Luo, Y., Li, Y., Wan, J., Tang, Y., Yu, H., Jiang, Q., Yang, J., Expression pattern of peroxisome proliferator-activated receptors in rat hippocampus following cerebral ischemia and reperfusion injury. PPAR Res., 2012, 10.1155/2012/596394.
76. Werman, A., Hollenberg, A., Solanes, G., Bjorbaek, C., Vidal-Puig, A.J., Flier, J.S., Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and − 2 isoforms and influence of insulin. J. Biol. Chem. 272 (1997), 20230–20235.
77. Yakunin, E., Kisos, H., Kulik, W., Grigoletto, J., Wanders, R.J., Sharon, R., The regulation of catalase activity by PPAR γ is affected by α-synuclein. Ann. Clin. Transl. Neurol. 1 (2014), 145–159.
78. Yamamoto, K., Itoh, T., Abe, D., Shimizu, M., Kanda, T., Koyama, T., Nishikawa, M., Tamai, T., Ooizumi, H., Yamada, S., Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg. Med. Chem. Lett. 15 (2005), 517–522.
79. Yang, X., Cheng, B., Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J. Mol. Neurosci. 42 (2010), 145–153.
80. Yu, X., Shao, X.G., Sun, H., Li, Y.N., Yang, J., Deng, Y.C., Huang, Y.G., Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res. 1200 (2008), 146–158.